https://scholars.lib.ntu.edu.tw/handle/123456789/319845
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | ANDY SUN | en_US |
dc.contributor.author | Wang, Jeng-Tzung | en_US |
dc.contributor.author | JEAN-SAN CHIA | en_US |
dc.contributor.author | CHUN-PIN CHIANG | en_US |
dc.creator | Sun, A.;Wang, J.-T.;Chia, J.-S.;Chiang, C.-P. | - |
dc.date.accessioned | 2018-09-10T05:46:05Z | - |
dc.date.available | 2018-09-10T05:46:05Z | - |
dc.date.issued | 2006 | - |
dc.identifier.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-33645219921&partnerID=MN8TOARS | - |
dc.identifier.uri | http://scholars.lib.ntu.edu.tw/handle/123456789/319845 | - |
dc.description.abstract | BACKGROUND: Recurrent aphthous ulcerations (RAU) are common oral inflammatory lesions. Tumor necrosis factor (TNF)-α is an important inflammatory mediator and a critical cytokine for adequate host defense. Our previous studies have shown that 14-43% and 59-63% of patients in the ulcerative stage of major, minor or herpetiform RAU have significantly higher than normal serum levels of interleukin (IL)-6 and IL-8, respectively. In this study, we examined whether RAU patients in the ulcerative stage had a significantly higher than normal serum level of TNF-α and assessed whether treatment with levamisole can modulate serum TNF-α levels in RAU patients. METHODS: This study used a solid phase, two-site sequential chemiluminescent immunometric assay to determine the baseline serum levels of TNF-α in 146 patients with RAU, nine patients with traumatic ulcers (TU), and 54 normal control subjects. Fifty-five RAU patients with serum TNF-α levels higher than 5.0 pg/ml were treated with levamisole for 0.5-4 months and their serum TNF-α levels were measured after treatment. RESULTS: We found that 29% (42 of 146) RAU patients as well as 39% (24 of 61) major type, 20% (14 of 69) minor type, and 25% (four of 16) herpetiform type RAU patients had a serum level of TNF-α greater than the upper normal limit of 7.4 pg/ml. The mean serum level of TNF-α in patients with RAU (9.1 ± 1.0 pg/ml, P < 0.001), major type RAU (11.6 ± 1.9 pg/ml, P < 0.001), minor type RAU (6.9 ± 0.9 pg/ml, P < 0.005), or herpetiform type RAU (9.6 ± 2.7 pg/ml, P < 0.001) was higher than that (3.8 ± 0.2 pg/ml) in normal control subjects. The mean serum TNF-α level was significantly higher in patients with major type RAU than in patients with minor type RAU (P < 0.05) and was significantly higher in major type RAU patients in the exacerbation stage than in the post-exacerbation stage (P < 0.05). In 55 RAU patients with serum TNF-α levels higher than 5.0 pg/ml, treatment with levamisole for a period of 0.5-4 months could significantly reduce the serum TNF-α level from 16.4 ± 1.9 to 5.8 ± 0.6 pg/ml (P < 0.001). CONCLUSIONS: We conclude that a significantly higher than normal serum level of TNF-α can be detected in 20-39% of patients in the ulcerative stage of major, minor or herpetiform RAU. The serum TNF-α level may be associated with the severity and the stage of RAU. Levamisole can modulate serum TNF-α levels in RAU patients. ? Blackwell Munksgaard 2006. All rights reserved. | en_US |
dc.language | en | en |
dc.relation.ispartof | Journal of Oral Pathology and Medicine | en_US |
dc.source | AH | - |
dc.subject | Levamisole; Recurrent aphthous ulcerations; Tumor necrosis factor-α | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | cytokine; interleukin 6; interleukin 8; levamisole; tumor necrosis factor alpha; adult; aged; aphthous ulcer; article; chemoluminescence; controlled study; disease association; disease classification; disease exacerbation; disease severity; female; host resistance; human; injury; major clinical study; male; priority journal; school child; staging; Adjuvants, Immunologic; Adolescent; Adult; Aged; Child; Female; Follow-Up Studies; Humans; Inflammation Mediators; Levamisole; Male; Middle Aged; Mouth Mucosa; Oral Ulcer; Recurrence; Stomatitis, Aphthous; Stomatitis, Herpetic; Tumor Necrosis Factor-alpha | - |
dc.title | Levamisole can modulate the serum tumor necrosis factor-α level in patients with recurrent aphthous ulcerations | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1111/j.1600-0714.2006.00383.x | - |
dc.relation.pages | 111-116 | en_US |
dc.relation.journalvolume | 35 | en_US |
dc.relation.journalissue | 2 | en_US |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Clinical Dentistry | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Oral Biology | - |
crisitem.author.dept | Microbiology | - |
crisitem.author.dept | Dentistry-NTUH | - |
crisitem.author.dept | School of Dentistry | - |
crisitem.author.dept | Oral Biology | - |
crisitem.author.orcid | 0000-0002-4912-5424 | - |
crisitem.author.orcid | 0000-0002-5431-0712 | - |
crisitem.author.orcid | 0000-0002-6190-7162 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 口腔生物科學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。